Adding Tucatinib to T-DM1 Improves PFS in Previously Treated HER2-positive Advanced Breast Cancer, Including Patients with Brain Metastases By Ogkologos - November 28, 2025 73 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the HER2CLIMB-02 study Source RELATED ARTICLESMORE FROM AUTHOR Lung Cancer Death Rates Among Women in Europe Are Finally Levelling Off A Combination of Savolitinib and Osimertinib Prolongs PFS in Patients with EGFR-mutated NSCLC and Acquired MET Amplification After Progression On a First-Line EGFR TKI EMA Recommends Granting a Conditional Marketing Authorisation for Nogapendekin alfa Inbakicept MOST POPULAR Get to Know CaringBridge June 3, 2021 EMA Recommends Granting a Conditional Marketing Authorisation for Idecabtagene Vicleucel June 28, 2021 A Third Of Breast Cancer Survivors Have Vaginal Atrophy, But Most... May 15, 2020 Flame of Hope Awards: Celebrating our volunteers April 3, 2023 Load more HOT NEWS Study Provides Closer Look at Postmenopausal Bleeding and Endometrial Cancer pCR Correlates with RFS and OS with Neoadjuvant Therapy in Stage... The ecDNA story – catching the mastermind behind cancer evolution Army Veteran Gets Life-Saving Heart Transplant: ‘It’s A True Miracle’
